FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 586 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Are Cancer Patients Getting the Opioids They Need to Control Pain? September 16, 2020 Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 Load more HOT NEWS FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... How Exercise Can Help You Cope With the Mental and Emotional... Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced...
